Today: 22 January 2026
Subscribe
Browse Category

Pharmaceuticals News 3 January 2026 - 5 January 2026

Ironwood Pharmaceuticals stock rises premarket after Citizens upgrade, Wells Fargo target lift

Ironwood Pharmaceuticals stock rises premarket after Citizens upgrade, Wells Fargo target lift

NEW YORK, Jan 5, 2026, 06:09 ET — Premarket Ironwood Pharmaceuticals shares rose about 1% in premarket trading on Monday after Citizens upgraded the gastrointestinal drugmaker, arguing that pricing pressure on Linzess has eased. Citizens analyst Jason Butler wrote that “LINZESS headwinds have passed” as the stock traded at $4.32 at 6:01 a.m. ET; Wells Fargo also lifted its price…
5 January 2026
····
GSK share price today: why the stock dipped after China approved Nucala for COPD

GSK share price today: why the stock dipped after China approved Nucala for COPD

LONDON, Jan 5, 2026, 09:46 GMT — Regular session GSK shares edged lower on Monday after the drugmaker said China’s medicines regulator approved its Nucala treatment for a form of chronic obstructive pulmonary disease (COPD). The stock was down about 0.3% at 1,825.5 pence by 09:45 GMT.  Investing The China nod matters because it opens a new label for one…
5 January 2026
···
Merck stock in focus before Monday: Cidara deal deadline hits Jan. 6 as MRK sits near 52-week high

Merck stock in focus before Monday: Cidara deal deadline hits Jan. 6 as MRK sits near 52-week high

NEW YORK, Jan 4, 2026, 20:43 ET — Market closed Merck & Co shares closed up 1.1% on Friday at $106.45, leaving the stock within sight of a 52-week high ahead of Monday’s U.S. market reopen. MarketWatch The near-term focus is a tender offer — a takeover process where shareholders can sell stock directly for cash at a set price…
5 January 2026
···
Healthcare stock Ironwood jumps 27% on Linzess price cut and 2026 profit outlook

Healthcare stock Ironwood jumps 27% on Linzess price cut and 2026 profit outlook

NEW YORK, Jan 4, 2026, 13:54 ET — Market closed Ironwood Pharmaceuticals shares jumped 26.7% on Friday to close at $4.27, outpacing the broader healthcare stock complex after the company laid out a sharply higher 2026 outlook tied to its Linzess constipation drug. Investing The move matters because Ironwood is trying to prove it can generate steady cash flow from…
4 January 2026
····
Kymera Therapeutics stock extends slide as KYMR closes down 6.5% — what investors watch next

Kymera Therapeutics stock extends slide as KYMR closes down 6.5% — what investors watch next

NEW YORK, Jan 4, 2026, 11:20 ET — Market closed Kymera Therapeutics, Inc. (KYMR) shares closed down 6.5% on Friday at $72.76, extending a losing streak to seven consecutive sessions as the U.S. market heads into the first full trading week of 2026. The stock is down about 13% since Dec. 23 and roughly 29% below the record intraday high…
4 January 2026
····
Eli Lilly stock ends higher to start 2026 as traders eye JPM conference, earnings

Eli Lilly stock ends higher to start 2026 as traders eye JPM conference, earnings

NEW YORK, Jan 4, 2026, 10:17 ET — Market closed Eli Lilly and Co shares ended Friday up $5.44, or 0.5%, at $1,080.36, giving the drugmaker a firm start to 2026 as investors positioned for a packed run of healthcare catalysts in January and February. The move matters because Lilly is one of the market’s largest “growth” stocks — companies…
4 January 2026
····
Bristol-Myers Squibb (BMY) stock fell Friday — here’s what investors are watching next

Bristol-Myers Squibb (BMY) stock fell Friday — here’s what investors are watching next

NEW YORK, Jan 3, 2026, 17:25 ET — Market closed Bristol-Myers Squibb shares ended down 0.9% at $53.46 on Friday, after the company confirmed it will present at J.P. Morgan’s annual healthcare conference on Jan. 12. JPMorgan Chase The San Francisco conference is the sector’s first major investor gathering of the year, often setting the tone for how traders price…
3 January 2026
····
Pfizer stock today: PFE ends first 2026 session higher as pricing scrutiny returns and Feb. 3 results loom

Pfizer stock today: PFE ends first 2026 session higher as pricing scrutiny returns and Feb. 3 results loom

NEW YORK, Jan 3, 2026, 15:55 ET — Market closed Pfizer Inc (NYSE: PFE) shares last closed up 1.1% at $25.18 on Friday, after a weak finish to 2025. U.S. markets were closed on Saturday. The stock is starting 2026 with drug pricing back in focus, a recurring risk for big pharma that can weigh on sentiment. Drugmakers raised U.S.…
3 January 2026
····
Merck stock starts 2026 higher as Cidara tender-offer deadline hits next week

Merck stock starts 2026 higher as Cidara tender-offer deadline hits next week

NEW YORK, Jan 3, 2026, 15:08 ET — Market closed Merck & Co. (MRK) shares ended Friday up about 1.2% at $106.45. Nasdaq said the cash tender offer for Cidara Therapeutics is scheduled to expire one minute after 11:59 p.m. ET on Jan. 6, with the merger tentatively slated to close before the market opens Jan. 7. The exchange said…
3 January 2026
····
Healthcare Stocks Today: XLV edges up as drugmakers raise U.S. list prices on 350 medicines

Healthcare Stocks Today: XLV edges up as drugmakers raise U.S. list prices on 350 medicines

NEW YORK, Jan 3, 2026, 13:21 ET — Market closed Drugmakers are lifting U.S. list prices on hundreds of medicines as 2026 begins, putting drug-pricing politics back in focus for healthcare investors. The sector finished higher in Friday’s session, the last U.S. trading day before the weekend. Drugmakers plan to raise U.S. prices on at least 350 branded medicines for…
3 January 2026
····
Eli Lilly stock today: LLY ticks higher as drug-price resets and a fresh upgrade sharpen focus

Eli Lilly stock today: LLY ticks higher as drug-price resets and a fresh upgrade sharpen focus

NEW YORK, January 3, 2026, 10:33 ET — Market closed Eli Lilly and Company shares closed up 0.53% at $1,080.36 on Friday and were down 0.17% in after-hours trading at $1,078.50. The move matters because early January is when many drugmakers reset “list prices” — the published prices before rebates and insurer discounts — and those changes can shape negotiations…
3 January 2026
····
1 … 13 14 15 16 17 … 46

Stock Market Today

  • Barclays Raises WEC Energy Group Price Target to $110, Sees Slight Upside
    January 22, 2026, 2:34 PM EST. Barclays lifted its price target for WEC Energy Group (NYSE:WEC) from $105 to $110, projecting a modest 0.26% upside. The utility provider's stock trades near $109.72, with a market cap of $35.69 billion. Analyst ratings vary: one has a Strong Buy, six recommend Buy, seven Hold, and one a Sell, reflecting mixed sentiment. Earnings last quarter beat estimates at $0.83 per share, supported by 12.9% revenue growth to $2.10 billion, surpassing analyst expectations. WEC Energy's 2025 earnings guidance ranges between $5.17 and $5.27 per share. Despite a modest price target increase, sentiment remains cautious amid varied analyst views and moderate trading volumes.
Go toTop